Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiological study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. CRA509-CRA509
Author(s):  
V. Dezentje ◽  
N. J. Van Blijderveen ◽  
H. Gelderblom ◽  
H. Putter ◽  
M. P. Van Herk-Sukel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Pharmacoepidemiological Study ◽  
Final Text ◽  
Financial Relationships

CRA509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. CRA501-CRA501 ◽  
Author(s):  
A. Tutt ◽  
M. Robson ◽  
J. E. Garber ◽  
S. Domchek ◽  
M. W. Audeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Parp Inhibitor ◽  
Advanced Breast ◽  
Final Text

CRA501 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA9084-LBA9084
Author(s):  
M. A. Henderson ◽  
B. Burmeister ◽  
J. F. Thompson ◽  
J. Di Iulio ◽  
R. Fisher ◽  
...  
Keyword(s):  
Lymph Node ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Adjuvant Radiotherapy ◽  
Regional Lymph Node ◽  
Field Control ◽  
Melanoma Patients ◽  
Final Text ◽  
Financial Relationships

LBA9084 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA5508-LBA5508
Author(s):  
S. Pignata ◽  
G. Scambia ◽  
A. Savarese ◽  
R. Sorio ◽  
E. Breda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Liposomal Doxorubicin ◽  
Advanced Ovarian Cancer ◽  
Multicenter Trial ◽  
Final Text ◽  
Financial Relationships

LBA5508 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology(WECARE) Study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA9513-CRA9513
Author(s):  
Chaya S. Moskowitz ◽  
Joanne F. Chou ◽  
Suzanne L. Wolden ◽  
Jonine L. Bernstein ◽  
Jyoti Malhotra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Childhood Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Childhood Cancer Survivors ◽  
Daily News ◽  
Online Supplement ◽  
Radiation Epidemiology ◽  
Childhood Cancer Survivor Study ◽  
Final Text

CRA9513 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA506-LBA506 ◽  
Author(s):  
Andre Robidoux ◽  
Gong Tang ◽  
Priya Rastogi ◽  
Charles E. Geyer ◽  
Catherine A. Azar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Operable Breast Cancer ◽  
Daily News ◽  
Online Supplement ◽  
B 41 ◽  
Final Text

LBA506 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA509-LBA509
Author(s):  
Gabriel N. Hortobagyi ◽  
Martine J. Piccart-Gebhart ◽  
Hope S. Rugo ◽  
Howard A. Burris ◽  
Mario Campone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Hormone Receptor ◽  
Daily News ◽  
Online Supplement ◽  
Molecular Alterations ◽  
Hormone Receptor Positive ◽  
Final Text

LBA509 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. CRA1008-CRA1008 ◽  
Author(s):  
G. Thomas Budd ◽  
William E. Barlow ◽  
Halle C. F. Moore ◽  
Timothy J. Hobday ◽  
James A. Stewart ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

CRA1008 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3-3 ◽  
Author(s):  
J. O'Shaughnessy ◽  
C. Osborne ◽  
J. Pippen ◽  
M. Yoffe ◽  
D. Patt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Ii ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Phase Ii Trial ◽  
Randomized Phase Ii ◽  
Final Text

3 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA515-LBA515
Author(s):  
L. J. Esserman ◽  
C. Perou ◽  
M. Cheang ◽  
A. DeMichele ◽  
L. Carey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Tumor Response ◽  
Molecular Profiles ◽  
Final Text

LBA515 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA4-LBA4 ◽  
Author(s):  
N. Wolmark ◽  
G. Yothers ◽  
M. J. O'Connell ◽  
S. Sharif ◽  
J. N. Atkins ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Stage Ii ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Carcinoma Of The Colon ◽  
Final Text ◽  
Financial Relationships

LBA4 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document